Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 6,831 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 6,831 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $657,073.89. Following the sale, the chief executive officer directly owned 169,402 shares of the company’s stock, valued at $16,294,778.38. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Christopher Peetz also recently made the following trade(s):

• On Thursday, January 22nd, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $662,456.34.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $99.27 on Wednesday. The company has a market cap of $5.10 billion, a PE ratio of -115.43 and a beta of 0.48. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The stock has a 50-day moving average price of $78.36 and a two-hundred day moving average price of $71.54. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $99.44.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s revenue was up 47.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on MIRM shares. JMP Securities set a $95.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Evercore ISI reissued an “outperform” rating and issued a $101.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. Morgan Stanley upped their target price on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.92.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Mirum Pharmaceuticals by 22.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,815 shares of the company’s stock worth $1,170,000 after purchasing an additional 2,700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 377.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,274 shares of the company’s stock worth $733,000 after buying an additional 7,332 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $240,000. Wetzel Investment Advisors Inc. bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at $205,000. Finally, Palumbo Wealth Management LLC grew its holdings in Mirum Pharmaceuticals by 19.8% during the 4th quarter. Palumbo Wealth Management LLC now owns 5,082 shares of the company’s stock worth $401,000 after acquiring an additional 840 shares in the last quarter.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron purchased 131,425 shares at $68.48 (≈$9.0M), increasing his stake by ~40%, a strong insider vote of confidence in the company and its valuation. Director Form 4
• Positive Sentiment: HC Wainwright upgraded MIRM to Buy, raised the price target from $102 to $130 and published an aggressive FY2030 EPS projection ($6.16), signaling bullish long‑term expectations from a coverage analyst and supporting higher share valuations. HC Wainwright Coverage
• Positive Sentiment: Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare-disease pipeline and global footprint—an acquisition likely viewed as strategically accretive and supportive of future revenue growth. Acquisition Announcement
• Positive Sentiment: Coverage and market reaction have pushed MIRM to a new 52‑week high following the analyst upgrade, which can attract momentum/technical buyers. 52‑Week High Article
• Negative Sentiment: CEO Christopher Peetz sold 6,831 shares at ~$96.19 (~$657K), reducing his stake by ~3.9%. CEO Form 4
• Negative Sentiment: Other senior exec sales the same day: COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares) and SVP Jolanda Howe (842 shares) — these reduce insider holdings and may concern some investors about near‑term insider liquidity. COO Form 4 CFO Form 4 SVP Form 4

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.